Labcorp Holdings Inc. (NYSE:LH) Stock Has Average Target Price of $337.73 According to Brokerages

Shares of Labcorp Holdings Inc. (NYSE:LH) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $365.67.

A number of research firms recently issued reports on LH. Morgan Stanley reissued an “overweight” rating and issued a $388.00 price objective on shares of Labcorp in a report on Thursday. Leerink Partners set a $410.00 target price on shares of Labcorp in a report on Wednesday. Bank of America increased their price target on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $355.00 price target on shares of Labcorp in a research note on Thursday. Finally, Piper Sandler boosted their price objective on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th.

Insider Buying and Selling

In other Labcorp news, EVP Amy B. Summy sold 924 shares of the company’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total value of $283,427.76. Following the completion of the sale, the executive vice president owned 6,956 shares in the company, valued at $2,133,683.44. This represents a 11.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Adam H. Schechter sold 4,669 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the completion of the sale, the chief executive officer owned 102,565 shares of the company’s stock, valued at approximately $32,858,749.05. The trade was a 4.35% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 8,593 shares of company stock valued at $2,733,295. 0.84% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Fifth Third Bancorp grew its position in shares of Labcorp by 106.5% during the first quarter. Fifth Third Bancorp now owns 57,981 shares of the medical research company’s stock valued at $15,470,000 after purchasing an additional 29,899 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Labcorp in the second quarter worth about $7,792,000. Tidal Investments LLC increased its holdings in shares of Labcorp by 12.4% in the second quarter. Tidal Investments LLC now owns 30,559 shares of the medical research company’s stock worth $8,557,000 after purchasing an additional 3,372 shares during the last quarter. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Labcorp in the second quarter worth about $168,222,000. Finally, Royal Bank of Canada lifted its position in shares of Labcorp by 19.4% in the first quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock worth $218,901,000 after buying an additional 133,549 shares in the last quarter. 95.94% of the stock is owned by hedge funds and other institutional investors.

Labcorp Stock Up 0.2%

LH stock opened at $361.96 on Monday. The company has a market cap of $29.35 billion, a price-to-earnings ratio of 29.69, a P/E/G ratio of 2.04 and a beta of 0.87. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.22 and a current ratio of 1.41. The business’s 50-day moving average is $323.23 and its two-hundred day moving average is $287.61. Labcorp has a fifty-two week low of $244.52 and a fifty-two week high of $371.00.

Labcorp (NYSE:LH) last released its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the company posted $4.18 EPS. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, analysts forecast that Labcorp will post 18.48 earnings per share for the current year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp’s dividend payout ratio (DPR) is currently 23.63%.

Key Stories Impacting Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reported third-quarter adjusted earnings of $4.78 per share, above the $4.64 consensus estimate, while revenue increased 6.9% year over year to $3.81 billion, topping expectations. The company also raised its outlook, supporting the investment case. Labcorp Q3 2026 Earnings Call Highlights
• Positive Sentiment: Truist raised its price target to $395 from $365 and maintained a Buy rating, while Robert W. Baird increased its target to $396 from $361 and retained an Outperform rating. The revisions indicate analysts see additional upside after the earnings beat. Truist Raises Labcorp Price Target
• Positive Sentiment: Zacks identified LH as a highly ranked value stock, potentially attracting investors seeking a combination of earnings strength and reasonable valuation characteristics. Labcorp Is a Top-Ranked Value Stock
• Neutral Sentiment: Labcorp’s estimated fair value moved modestly higher following third-quarter analyst revisions, suggesting improving expectations but limited near-term valuation support. Labcorp Fair Value Edges Higher
• Negative Sentiment: Analysts continue to flag potential pressure from changes to Medicare laboratory reimbursement rules under PAMA. That risk may temper the benefit of better earnings and guidance. Labcorp Stock Shrugs Off Q3 Earnings as PAMA Risk Looms
• Negative Sentiment: A Seeking Alpha contributor downgraded the stock, arguing that investor optimism and the sharp advance toward a 52-week high may have outpaced Labcorp’s underlying upside. Deutsche Bank raised its target to $355 but maintained a Hold rating, reinforcing valuation concerns. Labcorp Rating Downgrade

Labcorp Company Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.